Clinical update

Allergy Therapeutics PLC
04 July 2006


        Allergy Therapeutics plc, "Allergy Therapeutics" or "the Company"
                                        
  Successful end of Phase II meeting with FDA - Allergy Therapeutics to proceed
                 with Phase III development of Pollinex Quattro

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company 
focused on allergy vaccination, announced today that the Company has concluded 
a successful end of Phase II meeting with the Food and Drug Administration (FDA) 
in the United States for its ultra short course grass pollen allergy vaccine 
Pollinex(R) Quattro ('Grass MATAMPL').


Following a broad ranging review of Pollinex Quattro's preclinical,
manufacturing and clinical data, and, subject to minor clarifications, the FDA
has accepted the Company's plans to conduct a single pivotal Phase III trial for
registration of Pollinex Quattro Grass.


With a clear understanding of the path to achieve the regulatory submission, the
Company will now finalise preparations for a randomized, placebo-controlled,
double-blind study to confirm the efficacy of Pollinex Quattro in patients with
seasonal allergic rhinitis due to grass pollen exposure. Dosing of patients is
expected to commence in Q4 2006.


Evidence of the safety and efficacy of Pollinex Quattro has been established
through earlier clinical trials in Europe and is further supported in clinical
practice via the named patient use of the vaccine in over 74,000 patients.


Keith Carter, Chief Executive Officer of Allergy Therapeutics, said:


"We have been working with the Agency for nearly two years and share the aim of
making a standardized and rigorously tested allergy vaccine available for health
care professionals in the US."


"The market opportunity is vast, with the American Academy of Allergy Asthma and
Immunology estimating that 33 million allergy shots a year are given in the
United States alone."


Tom Holdich, Director of R&D said:


"This is an important milestone for the Company and follows two years of United
States focused development. The FDA's rigour and expertise are renowned and we
are pleased that their independent review of the technology and the development
programme has been achieved. A successful outcome of this Phase III trial will
open the door for Pollinex Quattro to become the first registered, next
generation allergy vaccine in the US.


"Pollinex Quattro has been designed to address the major unmet needs in allergic
rhinitis and , if confirmed, its therapeutic profile is truly transformational
compared with current treatments."


                                     -ends-


For further information, please contact:


Allergy Therapeutics plc


Keith Carter, Chief Executive Officer                        [phone]


Bell Pottinger


Dan de Belder / Emma Charlton                                [phone]




About Pollinex Quattro

There are three programmes of subcutaneous immunotherapy in clinical
development. The three programmes are Pollinex  Quattro Grass, Pollinex Quattro
Tree & Pollinex Quattro Ragweed, all of which are based on proprietary
technologies.   Preparations for initiating all three Phase III developments
later this year are well underway and collectively these  form the "Caution:
Allergen" programme. In addition there is an oral vaccine development currently
in phase II  development.

Pollinex Quattro vaccines contain three distinct technologies which act
synergistically.  Natural allergens are  chemically modified to improve safety
and allow for delivery of higher doses.  These are combined with a depot 
technology to provide prolonged desensitization and further improved
tolerability.   Finally, the immune response is  specifically enhanced and
directed by an adjuvant, monophosphoryl lipid A (MPL) (R).  MPL is a Toll-Like 4
Receptor  (TLR4) agonist and has been extensively tested in Pollinex Quattro and
other late stage and registered vaccines  including GlaxoSmithKline's Fendrix(R)
and Cervarix(R).






                      This information is provided by RNS
            The company news service from the London Stock Exchange